Journal Mobile Options
Table of Contents
Vol. 33, No. 1, 2012
Issue release date: January 2012
Cerebrovasc Dis 2012;33:80–85

Polymorphisms and Noncardioembolic Stroke in Three Case-Control Studies

Luke M.M. · Berger K. · Rowland C.M. · Catanese J.J. · Tong C.H. · Ross D.A. · Garcia V. · Kuhlenbaeumer G. · Ringelstein E.B. · Pullinger C.R. · Malloy M.J. · Deedwania P. · Ellis S.G. · Kane J.P. · Devlin J.J. · Lalouschek W. · Mannhalter C.
aCelera, Alameda, Calif., bCardiovascular Research Institute, UCSF, San Francisco, Calif., cDepartment of Medicine, UCSF Fresno, Fresno, Calif., and dThe Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, Ohio, USA; eInstitute of Epidemiology and Social Medicine and fDepartment of Neurology, University of Muenster, Germany; gMedical University Vienna, Vienna, Austria

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Gene variants associated with disease could reveal novel mechanisms. We searched for single nucleotide polymorphisms (SNPs) associated with noncardioembolic stroke (nonCES). Methods: We tested 24,926 SNPs in or near genes for association with nonCES in the Vienna Study (551 cases, 815 controls) and then evaluated the associated SNPs in the UCSF-CC Study (570 cases, 1,604 controls) first in pooled DNA samples and then in individual DNA samples. We then asked whether the risk alleles of the SNPs associated with increased risk in both studies were also associated with increased risk of nonCES in the German Study (728 cases, 1,041 controls). Results: Six of the 46 SNPs that were associated with nonCES in both the Vienna and the UCSF-CC Studies were also associated with nonCES in the German Study: rs362277 in HTT (OR 1.39, 90% CI 1.12–1.71), rs2924914 near CSMD1 (OR 1.22, 90% CI 1.04–1.43), rs1264352 near DDR1 (OR 1.20, 90% CI 1.02–1.41), rs544115 in NEU3 (OR 1.63, 90% CI 1.02–2.62), rs12481805 in UMODL1 (OR 1.31, 90% CI 1.01–1.81), and rs2857595 near NCR3 (OR 1.15, 90% CI 1.00–1.32). Accounting for multiple testing of 46 SNPs, these 6 SNPs had a false discovery rate of 0.69. Conclusions: Some of the 6 SNPs may be associated with nonCES but most may be false positives. These 6 SNPs merit investigation in additional nonCES study populations.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Pruissen DM, Kappelle LJ, Rosendaal FR, Algra A: Genetic association studies in ischaemic stroke: replication failure and prospects. Cerebrovasc Dis 2009;27:290–294.
  2. Meschia JF: Subtyping in ischemic stroke genetic research. J Stroke Cerebrovasc Dis 2002;11:208–219.
  3. Luke MM, Lalouschek W, Rowland CM, Catanese JJ, Bolonick JI, Bui ND, Greisenegger S, Endler G, Devlin JJ, Mannhalter C: Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: Vienna Stroke Registry. Cerebrovasc Dis 2009;28:499–504.
  4. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, Catanese JJ, Pullinger CR, Leong DU, Arellano AR, Tong CH, Movsesyan I, Naya-Vigne J, Noordhof C, Feric NT, Malloy MJ, Topol EJ, Koschinsky ML, Devlin JJ, Ellis SG: A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2030–2036.
  5. Berger K, Stogbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB, Funke H: The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet 2007;121:169–178.
  6. Vennemann MM, Hummel T, Berger K: The association between smoking and smell and taste impairment in the general population. J Neurol 2008;255:1121–1126.
  7. Shiffman D, O’Meara ES, Bare LA, Rowland CM, Louie JZ, Arellano AR, Lumley T, Rice K, Iakoubova O, Luke MM, Young BA, Malloy MJ, Kane JP, Ellis SG, Tracy RP, Devlin JJ, Psaty BM: Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008;28:173–179.
  8. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a new and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289–300.

    External Resources

  9. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 2000;155:945–959.
  10. Kubo M, Hata J, Ninomiya T, Matsuda K, Yonemoto K, Nakano T, Matsushita T, Yamazaki K, Ohnishi Y, Saito S, Kitazono T, Ibayashi S, Sueishi K, Iida M, Nakamura Y, Kiyohara Y: A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 2007;39:212–217.
  11. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, et al: The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 1993;4:398–403.
  12. Kraus DM, Elliott GS, Chute H, Horan T, Pfenninger KH, Sanford SD, Foster S, Scully S, Welcher AA, Holers VM: CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol 2006;176:4419–4430.
  13. Franco-Pons N, Tomas J, Roig B, Auladell C, Martorell L, Vilella E: Discoidin domain receptor 1, a tyrosine kinase receptor, is upregulated in an experimental model of remyelination and during oligodendrocyte differentiation in vitro. J Mol Neurosci 2009;38:2–11.
  14. Franco C, Hou G, Ahmad PJ, Fu EY, Koh L, Vogel WF, Bendeck MP: Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res 2008;102:1202–1211.
  15. Yoshizumi S, Suzuki S, Hirai M, Hinokio Y, Yamada T, Yamada T, Tsunoda U, Aburatani H, Yamaguchi K, Miyagi T, Oka Y: Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metabolism 2007;56:420–429.
  16. Nanetti L, Vignini A, Raffaelli F, Taffi R, Silvestrini M, Provinciali L, Mazzanti L: Sialic acid and sialidase activity in acute stroke. Dis Markers 2008;25:167–173.
  17. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG: Classification of stroke subtypes. Cerebrovasc Dis 2009;27:493–501.
  18. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG: New approach to stroke subtyping: The A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 2009;27:502–508.
  19. Matsushita T, Ashikawa K, Yonemoto K, Hirakawa Y, Hata J, Amitani H, Doi Y, Ninomiya T, Kitazono T, Ibayashi S, Iida M, Nakamura Y, Kiyohara Y, Kubo M: Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. Hum Mol Genet 2010;19:1137–1146.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50